The Use of Complementary and Alternative Medicine Supplements of Potential Concern during Breast Cancer Chemotherapy
Table 1
Patient characteristics ().
%
Racial background
Black or African American
3
0.9
White
317
90.6
Asian
7
2.0
Other
8
2.3
More than one race
2
0.6
Unknown/not reported
13
3.7
Ethnicity
Non-Spanish, non-Hispanic
252
72.0
Mexican, south or central American
5
1.4
Other Spanish origin (includes European)
21
6.0
Unknown/not reported
72
20.6
Current marital or partnership status
Married
255
72.8
Divorced
38
10.8
Single
25
7.1
Domestic partnership with opposite sex
20
5.7
Did not answer
8
2.3
Domestic partnership with same sex
4
1.1
Income
No income
24
6.8
Less than 25,000/year
34
9.7
25,000–50,000/year
63
18.0
50,000–100,000/year
126
36.0
More than 100,000/year
86
24.6
Did not answer
17
4.8
Stage at dx
Stage 0
20
5.7
Stage I
112
32.0
Stage II
147
42.0
Stage III
61
17.4
Stage IV
7
2.0
Unknown
3
0.9
Conventional treatments received at time of BLQQ
Surgery
337
96.3
Chemotherapy
221
63.1
Radiation
251
71.7
Chemotherapy without radiation
89
25.4
Radiation without chemotherapy
119
34.0
Both radiation and chemotherapy
132
37.7
Type of chemotherapy received at time of BLQQ
Capecitabine
5
1.4
Carboplatin
38
10.8
Cyclophosphamide, IV
167
47.7
Cyclophosphamide, oral
15
4.3
Docetaxel
101
28.9
Doxorubicin
105
30.0
Lapatinib
3
0.9
Methotrexate
14
4.0
Vinorelbine
4
1.1
5-FU
16
4.6
CAM treatment received
CAM substance use
235
67.1
Consultation with CAM provider
134
38.3
Ppts are those women that had begun chemotherapy or radiation by the time of their BLQQ, according to CSS and abstracted medical records. Racial background, ethnicity, current marital or partnership status, and income are taken from the baseline QQ. Stage and conventional treatments are taken from CSS. Type of chemotherapy received is taken from ppt medical record abstraction. Numbers for type of chemotherapy ≥350 with ≥1 chemo per woman. CAM provider includes ND, Chinese medicine, massage, and chiropractor.
